Objective-Peroxisome proliferator-activated receptor-␣ (PPAR␣) is a ligand-activated transcription factor that controls lipid metabolism and inflammation. PPAR␣ is activated by fibrates, hypolipidemic drugs used in the treatment of dyslipidemia. Previous studies assessing the influence of PPAR␣ agonists on atherosclerosis in mice yielded conflicting results, and the implication of PPAR␣ therein has not been assessed. The human apolipoprotein E2 knock-in (apoE2-KI) mouse is a model of mixed dyslipidemia, atherosclerosis, and nonalcoholic steatohepatitis (NASH). The aim of this study was to analyze, using homo-and heterozygous PPAR␣-deficient mice, the consequences of quantitative variations of PPAR␣ gene levels and their response to the synthetic PPAR␣ agonist fenofibrate on NASH and atherosclerosis in apoE2-KI mice. Methods and Results-Wild-type (ϩ/ϩ), heterozygous (ϩ/Ϫ), and homozygous (Ϫ/Ϫ) PPAR␣-deficient mice in the apoE2-KI background were generated and subjected to a Western diet supplemented with fenofibrate or not supplemented. Western diet-fed PPAR␣Ϫ/Ϫ apoE2-KI mice displayed an aggravation of liver steatosis and inflammation compared with PPAR␣ϩ/ϩ and PPAR␣ϩ/Ϫ apoE2-KI mice, indicating a role of PPAR␣ in liver protection. Moreover, PPAR␣ expression was required for the fenofibrate-induced protection against NASH. Interestingly, fenofibrate treatment induced a similar response on hepatic lipid metabolism in PPAR␣ϩ/ϩ and PPAR␣ϩ/Ϫ apoE2-KI mice, whereas, for a maximal antiinflammatory response, both alleles of the PPAR␣ gene were required. Surprisingly, atherosclerosis development was not significantly different among PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice. However, PPAR␣ gene level determined both the antiatherosclerotic and vascular antiinflammatory responses to fenofibrate in a dose-dependent manner. Conclusion-These results demonstrate a necessary but quantitatively different role of PPAR␣ in the modulation of liver metabolism, inflammation, and atherogenesis. (Arterioscler Thromb Vasc Biol. 2011;31:1573-1579.)
F ibrates are lipid-lowering drugs widely used in clinical practice to treat dyslipidemia. 1 Studies performed in peroxisome proliferator-activated receptor-␣ (PPAR␣)-deficient mice have demonstrated that the hypolipidemic effects of fibrates are due to activation of PPAR␣, a ligand-activated transcription factor that modulates lipid metabolism. 2 PPAR␣ is expressed in many tissues, particularly in tissues with high fatty acid oxidation rates, such as liver, kidney, heart, and muscle. After activation by fibrates, PPAR␣ binds as a heterodimer with the retinoid X receptor to PPAR response elements in the promoters of genes implicated in lipid and lipoprotein metabolism. In addition to its effects on lipid metabolism, PPAR␣ also inhibits proinflammatory pathways by negatively interfering with other signaling pathways, such as nuclear factor-B, signal transducer and activator of transcription, or activator protein-1. Consequently, through its effects on lipid metabolism and inflammation, PPAR␣ may modulate pathophysiological pathways implicated in fatty liver disease and atherosclerosis. Data concerning the implication of PPAR␣ in liver steatosis and inflammation in humans is scarce. However, it has been shown that PPAR␣ agonist treatment decreases nonalcoholic steatohepatitis (NASH) development in wild-type mice fed a methionine choline-deficient diet 3, 4 and apolipoprotein E2 knock-in (apoE2-KI) mice or foz/foz mice fed a high-fat diet. 5, 6 Moreover, PPAR␣ is expressed in many cell types found in the atherosclerotic lesion, such as macrophages, endothelial cells, and smooth muscle cells. 7 In vitro and in vivo studies have suggested that fibrates could exert antiatherogenic actions by improving lipid abnormalities or by modulating several steps of atherogenesis, such as decreasing inflammation and thrombosis, directly in the vascular wall. In humans, fibrates decrease cardiovascular disease, especially in patients with high triglyceride and low high-density lipoprotein-cholesterol levels. 1 Moreover, we have previously shown that fenofibrate treatment reduces macrophage-laden atherosclerotic lesions in apoE2-KI mice, a mouse model of NASH, atherosclerosis, and mixed dyslipidemia. 8 However, the role of PPAR␣ in atherosclerosis is controversial, because PPAR␣ deficiency protects against atherosclerosis progression in apoE-deficient mice 9 and Tsukuba hypertensive mice, 10 whereas macrophage-specific PPAR␣ expression protects low-density lipoprotein receptor (LDLR)-deficient mice from atherosclerosis, 11 and PPAR␣ agonist treatment increases 12 or decreases 8, 13, 14 atherosclerosis development in different murine models.
In the present study, we aimed to analyze the consequences of PPAR␣ deficiency on lipid metabolism and inflammation in the vascular wall and the liver using apoE2-KI mice, a model of mixed dyslipidemia, atherosclerosis, and NASH, and to further explore the implication of PPAR␣ in the response to fenofibrate treatment. Therefore, wild-type (ϩ/ϩ), heterozygous (ϩ/Ϫ), and homozygous PPAR␣-deficient (Ϫ/Ϫ) apoE2-KI mice were fed a Western diet with or without fenofibrate during 9 weeks. Surprisingly, homozygous PPAR␣ deficiency did not modify plasma lipid concentrations; however, it aggravated liver steatosis and inflammation. Interestingly, PPAR␣ gene levels differently affected the response to fenofibrate on hepatic lipid metabolism and inflammation. In addition, whereas PPAR␣ deficiency did not influence atherosclerosis development, the PPAR␣ gene level dose-dependently controlled the response to fenofibrate on vascular inflammation and atherogenesis.
Materials and Methods

Animals
Homozygous PPAR␣-deficient mice on the C57BL/6 background 15 were crossed with homozygous human apoE2-KI mice, 16 which express human apoE2 instead of mouse apoe under control of the endogenous promoter, to generate PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice. Three-month-old female mice of the 3 genotypes (nϭ11 per group) were fed a Western diet containing 0.2% cholesterol and 21% fat (wt/wt) (UAR) without (control group) or with fenofibrate for 9 weeks. Based on food consumption, the dosage of fenofibrate corresponded to Ϸ100 mg/kg of body weight. Mice were maintained under a 12-hour light/dark cycle and had free access to water. All animal experiments were conducted with the approval of the Pasteur Institute review board, Lille, France.
Plasma Lipid and Lipoprotein Analyses
Mice were fasted for 4 hours before retro-orbital puncture under isoflurane-induced anesthesia. Plasma concentrations of total cholesterol (TC) and triglycerides (TG) were measured using commercially available kits (Biomerieux).
Hepatic Lipid Analysis
Frozen liver tissue (50 mg) was homogenized in SET buffer (1 mL; 250 mmol/L sucrose, 2 mmol/L EDTA, and 10 mmol/L Tris), followed by 2 freeze-thaw cycles, and 3 passages through a 27-gauge syringe needle, and a final freeze-thaw cycle to ensure complete cell lysis. Protein content was determined with the BCA method, and TG and cholesterol was measured as described above.
Liver Immunohistochemistry
Seven-micrometer frozen-cut liver sections were fixed in acetone and stained with Mac1 (M1/70) antibodies, as described. 5
Isolation of Primary Hepatocytes
Primary hepatocytes were isolated from the livers of fed mice, as previously described. 17 
RNA Extraction and Quantitative Polymerase Chain Reaction Analysis
RNA, isolated from livers using the acid guanidinium thiocyanate/ phenol/chloroform method, 18 was reverse transcribed using random hexamer primers and Moloney murine leukemia virus-reverse transcriptase (Invitrogen). RNA levels were determined by real-time quantitative polymerase chain reaction on a MX-4000 apparatus (Stratagene) using the Brilliant SYBR Green QPCR master mix (Stratagene) and specific primers. Results are expressed normalized to cyclophilin.
Atherosclerotic Lesion Analysis
At the end of the diet, mice were euthanized, and the hearts were perfused with cold Krebs-Ringer buffer and fixed in a solution containing 4% phosphate-buffered paraformaldehyde. Serial 10-mthick cryosections were cut between the valves and the aortic arch, and atherosclerotic lesions were quantified by Oil Red O staining. Images were captured using a JVC 3-CCD video camera and analyzed using the computer-assisted Quips Image analysis system (Leica Mikroskopic und System GmbH). Cryosections from aortic lesions were stained with anti-mouse monocyte/macrophage marker-2 (MOMA-2) (Santa Cruz Biotechnology) or anti-mouse monocyte chemoattractant protein-1 (MCP-1) (Santa Cruz Biotechnology). MCP-1 protein levels were semiquantitatively scored for staining on lesions of 4 mice per group.
Statistical Analysis
Results are expressed as the meansϮSE. Data were compared by ANOVA. Significant differences were subjected to post hoc analysis by using the Scheffe test. A value of PϽ0.05 was considered statistically significant.
Results
Homozygous PPAR␣ Deficiency Does Not Modify Plasma Lipid Concentrations but Aggravates Liver Steatosis and Inflammation in apoE2-KI Mice Fed a Western Diet
Female PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice were generated, and PPAR␣ mRNA levels were found to be intermediate and undetectable, respectively, in the livers of PPAR␣ϩ/Ϫ and PPAR␣Ϫ/Ϫ mice versus PPAR␣ϩ/ϩ apoE2-KI mice (Supplemental Figure IA, available online at http://atvb.ahajournals.org). These mice were fed a Western diet that was previously shown to induce liver steatosis and inflammation. 5 After 9 weeks of Western diet feeding, plasma TG and TC concentrations were similar in the 3 groups of mice ( Figure 1A and 1B). Relative liver weight was not different among the 3 genotypes (Supplemental Figure IB) , and liver cholesterol content was slightly but not significantly increased in PPAR␣Ϫ/Ϫ apoE2-KI compared with PPAR␣ϩ/ϩ and PPAR␣ϩ/Ϫ apoE2-KI mice (Supplemental Figure IC) . PPAR␣Ϫ/Ϫ apoE2-KI mice displayed more severe steatohepatitis, as illustrated by higher levels of liver TG ( Figure 1C ) and increased numbers of Mac1-positive cells ( Figure 1D ), compared with PPAR␣ϩ/ϩ mice. Interestingly, heterozygous PPAR␣ϩ/Ϫ apoE2-KI mice displayed a phenotype similar to that of PPAR␣ϩ/ϩ mice ( Figure 1C and 1D). These results demonstrate that PPAR␣ deficiency does not modify plasma lipid concentrations, and only homozygous PPAR␣ deficiency aggravates liver steatosis and macrophage content in Western diet-fed apoE2-KI mice.
PPAR␣ Activation Improves Plasma and Hepatic Lipid Homeostasis in PPAR␣؉/؉ and PPAR␣؉/؊ but not PPAR␣؊/؊ apoE2-KI Mice Fed a Western Diet
To determine the role of the PPAR␣ gene level on the hepatic and plasma response to its agonist fenofibrate, female PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice were fed a Western diet supplemented with fenofibrate for 9 weeks. The response to the PPAR␣ agonist was compared with the respective placebo-treated PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice, whose values were set at 100%. As expected, 8 fenofibrate treatment decreased plasma TC and TG concentrations (Figure 2A and 2B) and liver TG content ( Figure 2C ) in PPAR␣ϩ/ϩ apoE2-KI mice. In marked contrast, fenofibrate-treated PPAR␣Ϫ/Ϫ apoE2-KI mice did not exhibit any significant decrease in plasma TC and TG concentrations and liver TG levels compared with placebo-treated mice, showing that fenofibrate improves dyslipidemia and hepatic steatosis in a PPAR␣-dependent manner in apoE2-KI mice (Figure 2A to 2C). Interestingly, fenofibrate reduced plasma TC and TG concentrations and liver TG levels to the same extent in PPAR␣ϩ/Ϫ apoE2-KI as in PPAR␣ϩ/ϩ apoE2-KI mice. Because PPAR␣ is a transcription factor which regulates the expression of genes involved in fatty acid uptake and oxidation in parenchymal cells of the liver, mRNA levels for fatty acid translocase, very-long-chain acyl-CoA dehydrogenase, longchain acyl-CoA dehydrogenase, and medium-chain acyl-CoA dehydrogenase were measured ( Figure 3A to 3D). Fenofibrate 
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increased the hepatic expression levels of all these genes in PPAR␣ϩ/ϩ but not in PPAR␣Ϫ/Ϫ apoE2-KI mice. However, in PPAR␣ϩ/Ϫ apoE2-KI mice, the expression of these genes increased to an extent similar to that in PPAR␣ϩ/ϩ apoE2-KI mice on fenofibrate treatment. A comparable induction of genes implicated in hepatic lipid metabolism was also observed in primary hepatocytes isolated from PPAR␣ϩ/ϩ and PPAR␣ϩ/Ϫ apoE2-KI mice and treated with the specific PPAR␣ agonist GW647, whereas this induction was not observed in PPAR␣Ϫ/Ϫ apoE2-KI hepatocytes (Supplemental Figure IIA and IIB) . Thus, only 1 allele of the PPAR␣ gene is required for an optimal response to fenofibrate on dyslipidemia and liver steatosis.
PPAR␣ Activation Decreases Hepatic Inflammation and Macrophage Content in PPAR␣؉/؉ but not PPAR␣؉/؊ or PPAR␣؊/؊ apoE2-KI Mice Fed a Western Diet
Hepatic inflammation was analyzed in the fenofibrate-treated mice. Fenofibrate treatment decreased the number of Mac-1 positive cells, indicative of the number of macrophages, in livers of PPAR␣ϩ/ϩ but not PPAR␣ϩ/Ϫ or PPAR␣Ϫ/Ϫ apoE2-KI mice ( Figure 4A and 4B) . The expression of monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), which are implicated in monocyte/ macrophage recruitment in the liver ( Figure 4C to 4E), were decreased in fenofibrate-treated PPAR␣ϩ/ϩ apoE2-KI mice. By contrast, fenofibrate did not influence the expression of these inflammatory markers in livers of PPAR␣Ϫ/Ϫ apoE2-KI mice. Interestingly, fenofibrate-treated PPAR␣ϩ/Ϫ apoE2-KI mice exhibited an intermediary gene expression level of MCP-1, VCAM-1, and ICAM-1. Of note, repression of lipopolysaccharide-induced MCP-1 and VCAM-1 expression by the specific PPAR␣ agonist GW647 was most pronounced in isolated primary hepatocytes from PPAR␣ϩ/ϩ apoE2-KI mice, whereas an intermediary response was seen in PPAR␣ϩ/Ϫ apoE2-KI cells (Supplemental Figure  IIC and IID) . Thus, both PPAR␣ alleles are necessary for an optimal inhibition of the hepatic inflammatory response by fenofibrate in apoE2-KI mice fed a Western diet.
PPAR␣ Gene Levels Do Not Influence Atherogenesis but Determine the Atheroprotective Response to Fenofibrate in apoE2-KI Mice Fed a Western Diet
Because nonalcoholic fatty liver disease is now considered a risk factor for cardiovascular disease, 19 atherogenesis and vascular inflammation were assessed in PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice fed a Western diet supplemented or not with fenofibrate. Interestingly, the mean aortic lesion area, as measured by lipid staining with Oil Red O, did not differ significantly among PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice ( Figure 5A and 5B). As expected, 8 mean lesion area was significantly reduced by Ϸ80% in fenofibrate-treated PPAR␣ϩ/ϩ mice compared with controls (median: 0.030 mm 2 in treated mice versus 0.166 mm 2 in control mice; PϽ0.001) ( Figure 5A and 5B). By contrast, no effect was observed in fenofibratetreated PPAR␣Ϫ/Ϫ apoE2-KI mice (median: 0.137 mm 2 in treated mice versus 0.123 mm 2 in control mice; not significant). Interestingly, treatment of PPAR␣ϩ/Ϫ apoE2-KI mice with fenofibrate resulted in a significant intermediary decrease in atherosclerotic lesion area (median: 0.138 mm 2 in treated mice versus 0.185 in control mice; PϽ0.05), indicating a dose-response effect of PPAR␣ gene expression on arterial wall lipid accumulation. To determine whether the modifications in atherosclerotic lipid accumulation were associated with altered inflammation in the arterial wall, immunostaining for MOMA-2 (specific of macrophages) and MCP-1 was performed in the lesions. Both MOMA-2 ( Figure  5C ) and MCP-1 ( Figure 5D and 5E) colocalized with Oil Red O staining, were intense, and did not differ among PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice, in accordance with the comparable lesion areas among the 3 genotypes ( Figure 5A ). Treatment with fenofibrate strongly decreased MOMA-2 and MCP-1 staining in the lesions of PPAR␣ϩ/ϩ but not PPAR␣Ϫ/Ϫ apoE2-KI mice, indicating 
Discussion
Using apoE2-KI mice, a humanized mouse model of mixed dyslipidemia and NASH, 16 we show that homozygous PPAR␣ deficiency aggravates Western diet-induced steatosis and inflammation in the liver. This result is consistent with the reported increased hepatic steatosis observed in PPAR␣deficient mice in response to the physiological stimulus fasting, 20 -22 further illustrating the role of PPAR␣ in hepatic lipid metabolism. In apoE2-KI mice, aggravation of NASH induced by PPAR␣ deficiency was not accompanied by changes of plasma TC and TG concentrations or by atherosclerosis lesion development, suggesting a dissociation between the two pathological states. We also analyzed the effects of PPAR␣ gene level on the response to treatment with the PPAR␣ agonist fenofibrate on NASH. Fenofibrate treatment protected against NASH in Western diet-fed PPAR␣ϩ/ϩ but not PPAR␣Ϫ/Ϫ apoE2-KI mice, showing that the previously reported effects of fenofibrate on NASH in apoE2-KI mice 5 occur via PPAR␣. Interestingly, fenofibrate treatment of PPAR␣ϩ/Ϫ apoE2-KI mice resulted in decreased hepatic steatosis to an extent similar to that of PPAR␣ϩ/ϩ apoE2-KI mice. In parallel, the hepatic expression of genes implicated in fatty acid uptake and oxidation increased to a similar extent in fenofibrate-treated PPAR␣ϩ/Ϫ and PPAR␣ϩ/ϩ apoE2-KI mice. However, in contrast with the regulation of lipid metabolism, the antiinflammatory response to fenofibrate in the liver depends on both PPAR␣ alleles. Indeed, fenofibrate treatment strongly reduced inflammation and macrophage content in livers of PPAR␣ϩ/ϩ apoE2-KI mice (associated with decreased expression levels of MCP-1, ICAM-1, and VCAM-1), whereas little or no response to fenofibrate was observed in livers of PPAR␣ϩ/Ϫ apoE2-KI mice. Similar observations were made in isolated heterozygous primary hepatocytes treated with the specific PPAR␣ agonist GW647. Thus, PPAR␣ gene level differently influences fenofibrate's effects on hepatic steatosis and inflammation. A single PPAR␣ allele is sufficient for an optimal response of lipid metabolism to fenofibrate, whereas both alleles are required to obtain maximal antiinflammatory effects in the liver. 
Lalloyer et al PPAR␣ Level, Lipid Metabolism, and Inflammation
Until now, no null mutations of PPAR␣ have been identified in humans, but the hepatic PPAR␣ expression levels vary largely among individuals, 23 and several PPAR␣ mutations have been reported. 24, 25 Presently, the implication of PPAR␣ in fatty liver disease and a possible modulation by PPAR␣ agonists is still unclear. Magnetic resonance imaging analysis of liver fat in 15 type 2 diabetic patients has failed to show any changes in response to fenofibrate. 26 A pilot study in non-alcoholic fatty liver disease patients has shown that treatment with fenofibrate improves metabolic syndrome parameters, including the lipid profile, and has beneficial effects on certain liver function parameters, but its impact on liver histology was small. 27 Another study has suggested a beneficial effect of fenofibrate treatment, particularly in combination with statins, in reducing fatty liver disease. 28 Additional studies are needed to evaluate the impact of PPAR␣ agonists on non-alcoholic fatty liver disease, and in particular on the inflammatory component of NASH.
We showed that PPAR␣ is required for the fenofibrateinduced improvement of dyslipidemia in apoE2-KI mice and a single PPAR␣ allele is sufficient to mediate this effect, showing that PPAR␣ gene level does not determine the plasma lipid-response of fenofibrate. In the Lower Extremity Arterial Disease Event Reduction trial, PPAR␣ gene variation did not influence the magnitude of plasma TG lowering in response to bezafibrate, whereas genetic variation in the PPAR␣ gene affected the changes in plasma fibrinogen, an inflammatory response marker, to fibrate treatment. 29 Together with our data, variation in PPAR␣ gene activity or expression level appears of lesser impact on the lipid response to fibrate but of higher impact on the inflammatory response.
Because growing evidence links fatty liver disease to cardiovascular disease 19 and because apoE2-KI mice develop dyslipidemia and NASH, as well as atherosclerosis, we also assessed the role of PPAR␣ on vascular inflammation and atherosclerosis. Interestingly, despite the more severe NASH progression, PPAR␣ϩ/ϩ, PPAR␣ϩ/Ϫ, and PPAR␣Ϫ/Ϫ apoE2-KI mice developed quantitatively similar atherosclerotic lesion areas (as assessed by lipid, macrophage, and MCP-1 content of the atherosclerotic plaques), indicating that PPAR␣ does not modulate atherogenesis or vascular inflammation in apoE2-KI mice. This result is surprising because a study performed in LDLR-deficient mice demonstrated that macrophage PPAR␣ confers antiatherogenic effects via modulation of macrophage cholesterol trafficking and inflammatory activity. 11 Similar to the case in apoE2-KI mice, plasma lipid concentrations were not modified by PPAR␣ deficiency in these LDLR-deficient mice, indicating that differences in plasma lipids do not explain the observed discrepancies of lesion formation between the two models. The lesions in apoE2-KI mice consist mainly of foam cells, as occurs in the initial stages of atherogenesis in humans, whereas LDLRdeficient mice develop more advanced atherosclerotic plaques. 30 Thus, the PPAR␣ gene may not modulate the first stages of lesion formation but could influence the progression of atherosclerosis to more complex stages. Surprisingly, PPAR␣ deficiency in apoE-deficient mice, another mouse model of atherosclerosis characterized by a wide spectrum of lesions going from fatty streaks to fibro-proliferative lesions, 31 resulted in a protection against atherosclerotic lesion formation on Western diet feeding, notwithstanding a proatherogenic lipid profile characterized by higher levels of TG and TC. 9 However, in contrast to apoE2-KI mice, apoE-deficient mice do not respond to PPAR␣ agonists as humans do, displaying no change 13 or an increase 12 in plasma lipids on fibrate treatment, and therefore may not be a suitable model to study the impact of PPAR␣ agonists and possibly other lipid-lowering drugs on atherosclerosis. 30, 32 PPAR␣ activation with fenofibrate protected Western dietfed PPAR␣ϩ/ϩ but not PPAR␣Ϫ/Ϫ apoE2-KI mice against atherosclerosis progression, showing PPAR␣ dependency of the response to fenofibrate. Treatment of PPAR␣ϩ/Ϫ apoE2-KI mice with fenofibrate resulted in an intermediary level of atheroprotection and vascular antiinflammatory response (assessed by MOMA-2 and MCP-1 staining). Thus, the PPAR␣ gene level dose-dependently controls the response to its agonist on vascular inflammation and atherogenesis, despite a similar plasma lipid response in PPAR␣ϩ/ϩ and PPAR␣ϩ/Ϫ apoE2-KI mice. These observations suggest that atheroprotection on PPAR␣ activation, in addition to being determined by the plasma lipid concentrations, also depends on other parameters, such as inflammation in the artery wall and the liver.
The pathophysiological role of PPAR␣ in atherosclerosis has been investigated using 2 different and complementary strategies: genetic deficiency and a pharmacological intervention. PPAR␣ deficiency did not result in the opposite phenotype of fenofibrate-induced activation of PPAR␣ on atherosclerotic lesion areas. It is well established that nuclear-receptor deficiency does not always mirror ligand activation, which may be due to possible compensation mechanisms or the absence of active repression of target genes by the unliganded nuclear receptor via corepressor recruitment. However, the effects of fenofibrate did require PPAR␣ expression, because it was absent in PPAR␣Ϫ/Ϫ apoE2-KI mice.
In the Lopid Coronary Angiography Trial study, the PPAR␣ Val162 allele was associated with reduced progression of atherosclerosis, whereas the intron C allele was associated with greater progression of atherosclerosis. 29 In vitro, it has been shown that the Val162 variant displays higher PPAR response element-dependent transcriptional activity, 24, 33 whereas the intron 7 C allele was hypothesized to be associated with lower expression levels of PPAR␣. 29 Collectively, these results suggest that variations in PPAR␣ gene level or activity are associated with differential progression of atherosclerosis in humans. Neither PPAR␣ variant influenced plasma lipid concentrations in either study, suggesting that, in line with our results, PPAR␣ gene variation may influence atherosclerosis via mechanisms complementary to the PPAR␣ regulation of plasma lipid concentrations. Finally, because PPAR␣ agonists may selectively modulate the different activities of PPAR␣ (selective PPAR modulator effect), 34 the effects of PPAR␣ variants on the response to its agonists could be different according to the PPAR␣ agonist used. Thus, it will be of interest to study the impact of PPAR␣ variants on the responses to different agonists on fatty liver disease and to assess the association of modifications of lipid metabolism and inflammatory parameters with PPAR␣ polymorphisms. 
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